Commure’s latest funding round reads less like a startup press release and more like a subtle reset for how Wall Street thinks about AI in healthcare—less science project, more infrastructure play with real revenue attached.
A $6 Billion Reminder That Healthcare Runs…
The FDA’s latest reshuffle of its top drug and biologics leaders lands biotech in yet another plot twist—but this one may read more like a quirky chapter break than a full-blown cliffhanger for investors.
FDA’s New Cast at the Top
The Food…
In a quarter where the market preferred flashy AI tickers to unglamorous healthcare plumbing, P3 Health Partners (PIII) and Amwell (AMWL) quietly reported results that suggest the real work in healthcare is happening far from meme stocks and momentum screens. Both companies…
PACS Group, Inc. is giving Wall Street a reason to smile, with its Salt Lake City roots, NYSE ticker PACS, and a stock that is rallying smartly today while still showing solid gains over the year despite bouts of volatility.
From the Wasatch…
Family offices didn’t just come back to the deal table in April – they showed up with term sheets in one hand and stethoscopes in the other.
Healthcare Becomes the New Family Office Heirloom
After a cautious March tied to geopolitical jitters…
Amwell’s (NYSE: AMWL) first-quarter scorecard reads like a classic Wall Street turnaround chapter: the top line is shrinking, but the balance sheet is fortified, losses are tightening, and management is whistling its way toward cash-flow breakeven by year-end.
Cash, Costs and a…
Amwell’s (NYSE: AMWL) latest story is a quiet telehealth turnaround: a company that spent the last cycle building infrastructure now talking more about operating leverage, sticky SaaS, and a disciplined path to growth – all while the rest of digital health is…
Eli Lilly (LLY) has once again muscled its way to the top of the healthcare league tables, with its stock climbing as investors double down on the idea that obesity drugs are less a fad and more a new asset class. The…
